Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1
about
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Hepatitis C Virus (HCV)-Induced Immunoglobulin Hypermutation Reduces the Affinity and Neutralizing Activities of Antibodies against HCV Envelope ProteinStructural characterization of a human Fc fragment engineered for lack of effector functionsDeveloping the IVIG biomimetic, hexa-Fc, for drug and vaccine applicationsEpitope target structures of Fc-mediated effector function during HIV-1 acquisition.B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesTransfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesHigh mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient hostCarbamylation of immunoglobulin abrogates activation of the classical complement pathway.Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].Three-dimensional structure of the human myeloma IgG2.Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesThe solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.Macrophages are critical effectors of antibody therapies for cancerHIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humansPlasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis.Humoral immunity to HIV-1: neutralization and beyond.CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responsesAnti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL.Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?The role of humoral innate immunity in hepatitis C virus infection.Candidate antibody-based therapeutics against HIV-1.Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.Mouse and human FcR effector functions.A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization ActivityInsights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.HIV-specific antibody-dependent phagocytosis matures during HIV infection.Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.Engineered protease-resistant antibodies with selectable cell-killing functions.
P2860
Q26782237-BED957A6-AC28-438B-B437-D96AB0DD2E7DQ27486411-DA707D4F-A9B4-441F-BB46-E158774B237BQ27650876-36E68973-0143-44B2-A79E-A580E3952849Q30834514-7F295A40-FAA0-43AE-97E5-AC96D8D1361BQ33924272-8A0A320D-4284-47A7-B9EA-6C6B2A59CCBEQ34008741-BFC18B04-119A-4C70-B23F-3B823F7DCE36Q34057711-FCEAD1C0-F0E6-4A49-B0A1-2EFE8CAB3D5DQ34391256-79405965-A734-4AA5-8E8C-11CFD2A2138BQ34462167-380460FC-ECB6-4E9A-A03F-805B828D3A33Q34472287-1A96B852-674A-4DEF-A6F1-CE2B6795C333Q34516987-0D1AD0CE-4CB0-4BD1-8541-A33E2783AD3AQ34607919-0ACE1292-233B-408A-940A-3C05B9D8CD23Q34769388-3CD3B78C-83B3-4606-B85B-5E3578276F61Q35024276-8B960144-75A3-4864-9899-10960CF0AD5EQ35101333-E5F25F83-AA0D-485F-AFC6-CA7842A5B429Q35221593-805D51D8-27FC-4626-85C2-E4C3682EAEDCQ35857869-48A736AE-EEB4-479E-AF1F-4B63A15AF467Q36172128-1A13968E-E0EA-408C-9208-553FD218B948Q36213288-0DDA087C-6915-47F8-A19E-FFDFA167B633Q36252656-099C6F6B-9707-42DA-8579-8347D5638D3CQ36488868-346CE0CB-42CA-4293-A85E-6D363801CBBBQ36863847-2E16851A-19D7-4217-BC25-12904A1C3BDBQ37001971-D8FEF1AA-6545-442D-A518-AE23A582F466Q37088489-CAB02828-4EED-45DF-B800-B1CADDEA28C3Q37138991-F7CF59FA-0A41-4FD8-A260-BF0947D57DC1Q37256661-9A4601CB-5EA2-497B-B02D-4C7D2D447361Q37426168-21B9A97A-CFD4-4573-AE4D-4286EB737017Q37563516-E0E0A4B5-D8B9-44AF-990F-2A11A58687CEQ37677278-D2C5C7EE-8A33-4179-969D-88C415AE0A6CQ37733224-A1653A27-5A0A-4CE0-AE52-4E8A94798388Q37987129-FFDD97B6-E239-44D9-BF51-E1D436C0C5B3Q37998496-E613D0E7-F81D-42B0-823B-F151B3BCFDD6Q38324896-98099FEE-3152-491D-AFFE-037469E657EBQ38615349-1A639946-0ABB-46FF-A52A-07F7EB2FB9FBQ38631835-082EFB38-7179-45B8-8A8C-A6C27ABC208EQ38787430-23D03312-EBCD-4CEF-922B-4DB271FEA18FQ38847426-3A9563FC-EAF8-4530-BFB6-1C4CE241770BQ38873975-7E9384EE-D3E9-4159-AA79-AA0256156B43Q38998925-66ADDFC5-C561-4078-9E14-E03618C6C51FQ39103601-88287CCD-580D-4817-9364-3BC3AE4F44F6
P2860
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effector function activities o ...... immunodeficiency virus type 1
@ast
Effector function activities o ...... immunodeficiency virus type 1
@en
type
label
Effector function activities o ...... immunodeficiency virus type 1
@ast
Effector function activities o ...... immunodeficiency virus type 1
@en
prefLabel
Effector function activities o ...... immunodeficiency virus type 1
@ast
Effector function activities o ...... immunodeficiency virus type 1
@en
P2093
P2860
P1433
P1476
Effector function activities o ...... immunodeficiency virus type 1
@en
P2093
A J Hessell
J G van de Winkel
R C Jensen
P2860
P304
12161-12168
P356
10.1128/JVI.75.24.12161-12168.2001
P577
2001-12-01T00:00:00Z